PARP inhibitors as maintenance therapy in newly diagnosed advanced ovarian cancer: A meta-analysis.

CONCLUSIONS: PARPis are effective as maintenance therapy among patients with newly diagnosed advanced ovarian cancer after platinum-based chemotherapy, regardless of BRCA mutation or HRD status. PMID: 32654312 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32654312?dopt=Abstract

Source: BJOG : An International Journal of Obstetrics and Gynaecology - July 11, 2020 Category: OBGYN Authors: Lin Q, Liu W, Xu S, Shang H, Li J, Guo Y, Tong J Tags: BJOG Source Type: research